SUMMARY The hepatic involvement of 57 patients with systemic lupus erythematosus (SLE) was studied with special reference to liver membrane autoantibody (LMA). Liver abnormalities were found predominantly in patients with active SLE (27/48 (56%) in active SLE v 3/20 (15%) in inactive SLE). They were, however, rather mild or moderate and tended to disappear as the disease activity of SLE decreased. In this respect the liver abnormalities observed in this study differed from those in patients with lupoid hepatitis. The incidence of LMA in active SLE (8/11 (73%)) was significantly greater than that in inactive SLE (4/12 (33%)). The mean LMA index value in active SLE was 8*3, which was also greater than the 2*9 in inactive SLE. Furthermore, in active SLE the mean LMA titre was significantly higher in patients with liver abnormalities than in ti ose without. These results suggest that LMA may be associated with the activity of SLE and may be one of the factors which cause transient liver abnormalities.
It is well known that systemic lupus erythematosus (SLE) often presents various clinical features owing to multiple organ involvement. For example, lesions in the kidney, lung, or central nervous system have been widely investigated and commonly called lupus nephritis, lupus pneumonitis, and central nervous system lupus respectively.' On the other hand, clinical or aetiological aspects of hepatic involvement have not been seriously studied, 1-3 though a relatively high incidence of some liver abnormalities has been observed-20-70% in cases of SLE. [3] [4] [5] [6] [7] [8] Liver membrane autoantibody (LMA) was first detected in man by Hopf et al 9 in 1976 and has been found predominantly in patients with autoimmune chronic active hepatitisI0>l2 or lupoid hepatitis.13 To our knowledge, however, little is known about the role of LMA in the liver abnormalities occurring in patients suffering from SLE.
In this study we investigated the incidence and clinical features of liver abnormalities and the significance of LMA in association with SLE.
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Patients and methods

PATIENTS
Fifty seven patients with SLE, one male and 56 female, seen at Kyushu University Hospital between 1978 and 1987, were enrolled in this study. They fulfilled the 1982 revised criteria for the classification of SLE as proposed by the American Rheumatism Association.'4 The patients' mean age was 32 .5 years (range in Fig. 2a , the mean LMA index value in active SLE samples was significantly higher than that in inactive SLE (p<0-05). It was also found that among patients with active SLE the LMA index value was significantly higher in patients with liver abnormalities than in those without (p<O0O5) (Fig. 2b) Figure 3 shows that the LMA titre is inversely correlated with the CH50 value, which is one of the indices of disease activity. This result may support the above mentioned relation between LMA and disease activity of SLE. Moreover, in five patients whose SLE was initially active LMA titre fell as the disease activity of SLE decreased during a period of two to 12 months (Fig. 4) possibility that the LMA detected by radioimmunoassay might merely represent the presence of antinuclear antibodies. To rule out this possibility we observed the LMA by indirect immunofluorescence. The surface and cytoplasm of fixed rat hepatocytes were brightly stained, in addition to the staining of the nuclei, when LMA positive SLE serum was used (Fig. 5a ). By contrast, only the nuclei were found to be stained with the dark surface and cytoplasm when LMA negative SLE serum was used (Fig. 5b) . These results were confirmed using living rat hepatocytes; LMA positive SLE serum linearly stained only the cell surface, whereas LMA negative serum did not (photos not shown). In addition, the relation between LMA and antinuclear antibody titres was investigated. No specific relation between those two antibody titres was found (Fig. 6 ). These results indicate that the LMA assayed in this study is not a reflection of antinuclear antibodies.
Discussion
In this study we investigated the hepatic involvement in SLE and the association of LMA with the disease activity of SLE and liver abnormalities. Rothfield reported raised liver enzyme activities in about 30% of patients with SLE at the time of diagnosis when active disease was evident and found that they returned to normal with corticosteroid treatment. 3 Morito et al also observed a coincidental transaminase increase in 11/23 patients during an exacerbation of SLE.7 In our study liver abnormalities not due to drugs, but probably due to SLE, were found in 27/48 (56%) patients with active SLE and in only 3/20 (15%) of those with inactive SLE, which is compatible with previous reports. The increase of serum transaminase concentration was mild or moderate, and no patient had jaundice or an increase of total bilirubin. Dubois and Tuffanelli found jaundice in 3-8% of 520 patients with SLE. 2 Kofman et al observed hyperbilirubinaemia in 27% and jaundice in 12% of 25 patients with SLE. '6 In patients with SLE histologically non-specific and mild liver changes are common, Jut severe damage is rare.8 1 
